Keerat Singh, MD Orthopaedic Surgery - Orthopaedic Trauma Medicare: Accepting Medicare Assignments Practice Location: 3903 S Cobb Dr Se, Smyrna, GA 30080 Phone: 404-778-3350 |
Frederick P Wener, MD Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 3969 South Cobb Drive, Suite 108, Smyrna, GA 30080 Phone: 770-436-0041 Fax: 770-436-0335 |
Andrew H Milby, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3903 S Cobb Dr Se, Smyrna, GA 30080 Phone: 404-778-3350 Fax: 404-778-6548 |
Dr. Nina Suh, Orthopaedic Surgery - Hand Surgery Medicare: Accepting Medicare Assignments Practice Location: 3903 S Cobb Dr Se Ste 275, Smyrna, GA 30080 Phone: 404-251-2119 Fax: 404-251-2104 |
Miguel A Jimenez, M.D. Orthopaedic Surgery - Orthopaedic Surgery of the Spine Medicare: Medicare Enrolled Practice Location: 3903 S Cobb Dr Se, Suite 105, Smyrna, GA 30080 Phone: 678-838-6600 Fax: 770-438-1477 |
W. Joseph Absi, MD Orthopaedic Surgery - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 4485 S Cobb Dr Se Ste 100, Smyrna, GA 30080 Phone: 404-768-1133 Fax: 404-768-0309 |
News Archive
The Wellcome Trust spends over 600 million pounds each year to support its mission to foster and promote research with the aim to improving human and animal health. This funding supports basic research as well as technology transfer, the transfer of academic knowledge and technology to the corporate environment.
The Zika virus was present in Haiti several months before the first Zika cases were identified in Brazil, according to new research by infectious-disease specialists at the University of Florida.
By attaching specialized molecules to the backbone of DNA, researchers have made it easier to detect rare molecules associated with early disease.
The salivary glands of some tick species could become important research tools for studying how viruses are transmitted from ticks to mammals, and for developing preventive medical countermeasures.
Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.
› Verified 6 days ago